EN DE

Sinopharm Group Co Ltd (1099) Fair Value & Analysis

Healthcare · HK · Market cap HK$49.6B (≈ $6.3B) · ISIN CNE100000FN7

What is Sinopharm Group Co Ltd really worth?

SG Sinopharm Group Co Ltd 1099 · HK
PriceHK$15.69
Fair ValueHK$58.67
Upside+273.9%
Quality56/100

A solid business, trading 73% below our fair value of HK$58.67.

Watch Sinopharm Group Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Low debt · generates free cash flow
✓Ranks above peers (9/13)

Risks

!Mixed Growth (revenue 5y +4.7 %/yr)
!Thin margins · 1.2% net margin
!Narrow moat 25/100
!Evidence only medium, so the estimate is less certain

For context

·5.04% dividend yield
Evidence: Medium Range HK$44.00 – HK$73.33

Fair value as of: Aug 13, 2026

From 24 valuation models · updated 22 days ago

Share price −9.1% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price is below even our cautious bear case (HK$44.00). The market is more pessimistic than our downside scenario.
  • Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

HK$23.87 HK$12.35 Fair Value HK$58.67 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$12.35 – HK$23.87 · fair‑value band HK$44.00 – HK$73.33 · the HK$15.69 price screens below the HK$58.67 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Sinopharm Group Co Ltd (1099) currently trades at HK$15.69, while our model-based Fair Value estimate is HK$58.67, implying the stock looks roughly 73.3% undervalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of HK$100.68 per share, and 24 of the 24 models we run sit above the HK$15.69 price. Bear case: the Asset-Based group reads lowest at HK$18.03, and 0 of the 24 models stay below the price. Evidence for this calculation is medium.

Over the trailing twelve months, Sinopharm Group Co Ltd generated revenue of HK$574B at a net margin of 1.2%. Revenue declined 0.6% year over year. It earns a return on equity of 8.1%. Net debt stands at HK$47.0B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$44.00 (bear case) to HK$73.33 (bull case); at HK$15.69, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 274%, 1099 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$2.14 per share. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF best evidence HK$69.54 HK$109.24 HK$177.28 78
Growth DCF HK$69.31 HK$106.16 HK$167.90 76
Residual Income HK$22.74 HK$24.62 HK$30.94 75
All 24 models by family
DCF Models
FCF DCF best evidence HK$69.54 HK$109.24 HK$177.28 78
Owner Earnings HK$58.57 HK$89.73 HK$143.13 74
5Y Revenue Exit HK$66.19 HK$101.48 HK$149.06 71
5Y EBITDA Exit HK$77.55 HK$124.64 HK$183.37 73
5Y P/E Exit HK$58.57 HK$85.93 HK$116.61 70
10Y Revenue Exit HK$65.31 HK$99.10 HK$150.12 65
10Y EBITDA Exit HK$74.39 HK$115.96 HK$178.54 67
10Y P/E Exit HK$61.86 HK$87.78 HK$123.25 63
Earnings-Based
Graham-Dodd HK$15.59 HK$69.55 HK$95.28 61
Lynch FV HK$18.07 HK$25.82 HK$33.56 58
PEG = 1.0 HK$18.07 HK$25.82 HK$33.56 55
EPV HK$55.41 HK$61.56 HK$66.93 72
Multiples
P/E Multiple HK$37.83 HK$50.44 HK$63.05 61
P/S Multiple HK$29.23 HK$38.98 HK$48.72 56
P/B Multiple HK$29.23 HK$38.98 HK$48.72 53
EV/EBIT HK$84.10 HK$105.94 HK$127.78 65
EV/EBITDA HK$86.97 HK$109.76 HK$132.56 66
EV/Revenue HK$65.34 HK$85.38 HK$105.43 53
Asset-Based
NCAV (Graham) HK$13.46 HK$18.03 HK$26.92 52
Growth DCF
Growth DCF HK$69.31 HK$106.16 HK$167.90 76
Rev-Margin DCF HK$66.19 HK$100.68 HK$144.66 71
Economic Profit
Residual Income HK$22.74 HK$24.62 HK$30.94 75
ROIC Compounder HK$58.81 HK$69.76 HK$82.48 71
Growth Earnings
Growth-Adj P/E HK$30.32 HK$43.31 HK$56.30 66

Widest divergence: Growth DCF (HK$100.68) versus Asset-Based (HK$18.03). Highest evidence: FCF DCF (78).

Notify me when 1099 reaches fair value

Put 1099 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 6.0 as of Jul 2, 2026
P/S ratio 0.07 P/E × margin
EPS (TTM) HK$3.94 price ÷ EPS = P/E 6.0
Dividend yield 5.0% payout 20.0%
Net margin 1.2% FY2025
Return on equity 8.1% TTM
More key figures
Profitability
Return on assets (EBIT) 5.0% avg 5y
Operating margin 2.2% TTM
Growth
Revenue (TTM) HK$574B TTM
Revenue growth (YoY) −0.6% 3y avg +1.4%
EPS growth (YoY) −4.3%
Balance sheet & cash flow
Free cash flow HK$12.5B FY2025
Net debt HK$47.0B FY2025 · ≈ 3.8 yrs of FCF

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 56/100

Of which business quality 56 · Market factors (momentum, volatility) 43

Profitability 41
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 58
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 84
Disciplined investing over empire-building
Low Volatility 93
Calm price path (market factor)
Momentum 27
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business.

Full company description

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products. The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Sinopharm Group Co Ltd reported revenue of 575B CNY in FY2025 versus 521B CNY in FY2021, a compound +2.5%/yr. Reported net income was 7.2B CNY in FY2025, compounding −2.0%/yr from FY2021.

Growth Quality 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$575B
Latest YoY
−1.6%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.4%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.7%
Avg. revenue growth/yr (19Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+18.3%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+3.3% (−1.7 + 5.0)
Revenue +2.5%/yr
FY21 521B CNY
FY22 552B CNY
FY23 597B CNY
FY24 585B CNY
FY25 575B CNY
Net income −2.0%/yr
FY21 7.8B CNY
FY22 8.5B CNY
FY23 9.1B CNY
FY24 7.0B CNY
FY25 7.2B CNY
Character of growth · EPS growth decomposed (2014-2025) +6.7 % p.a.
Revenue per share +9.3 %

of which total revenue +11.0 % · buybacks/dilution −1.6 %

EBIT margin −3.1 %
Tax rate −0.5 %
Residual (interest, one-offs) +1.2 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

Watch 1099: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sinopharm Group Co Ltd · Fair Value
HK$58.67 +73%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sinopharm Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1099

Peer Group

Medical Distribution · 78 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 56 · Above median
Return on equity (TTM) 8% · Above median
Return on assets 3% · Above median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 2% · Below median
Revenue growth −1% · Below median
Dividend yield (TTM) 5.0% · Top 25%
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Medical Distribution median · lower = cheaper

P/E (TTM) 6.0× · Cheaper than 75% of peers
P/B 0.59× · Cheaper than median
P/S (TTM) 0.09× · Cheaper than 75% of peers
P/FCF 0.5× · Cheaper than median
PEG 2.31× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 26
FUTURE0 · sector 14
PAST32 · sector 22
HEALTH98 · sector 97
DIVIDEND100 · sector 57

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $906.77 $819.31 −10%
Cencora, Inc COR $330.97 $211.07 −36%
Cardinal Health, Inc CAH $234.55 $141.77 −40%
Henry Schein, Inc HSIC $88.46 $71.70 −19%
Shanghai Pharmaceuticals Holding 601607 ¥16.37 ¥33.96 +107%
Galenica AG GALE CHF 80.85 CHF 61.79 −24%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥21.03 ¥28.65 +36%
Jointown Pharmaceutical Group 600998 ¥5.04 ¥9.84 +95%
Asker Healthcare Group ASKER kr 74.40 kr 28.26 −62%
China National Medicines Corporation 600511 ¥26.84 ¥58.22 +117%

Compare Sinopharm Group Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Sinopharm Group Co Ltd (1099) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$58.67 versus a price of HK$15.69, about +274% upside (undervalued).
What is the fair value of 1099?
Our model-based fair value for Sinopharm Group Co Ltd is HK$58.67 (as of Aug 13, 2026), built from audited fundamentals. The current price: HK$15.69.
What is the quality score of 1099?
Sinopharm Group Co Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Sinopharm Group Co Ltd (1099)?
Sinopharm Group Co Ltd reported trailing-twelve-month revenue of about HK$574B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 1099?
The net profit margin of Sinopharm Group Co Ltd is about 1.2%, meaning it keeps roughly 1.2% of revenue as net income. Based on the latest reported figures.
Does Sinopharm Group Co Ltd pay a dividend?
Sinopharm Group Co Ltd currently shows a dividend yield of about 5.04% relative to its recent price (as of Aug 13, 2026).
Free · no account needed

Watch Sinopharm Group Co Ltd in the live analysis

One click puts Sinopharm Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.